JP2015504430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504430A5 JP2015504430A5 JP2014542299A JP2014542299A JP2015504430A5 JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5 JP 2014542299 A JP2014542299 A JP 2014542299A JP 2014542299 A JP2014542299 A JP 2014542299A JP 2015504430 A5 JP2015504430 A5 JP 2015504430A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- allele
- seq
- patient
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ3702011 | 2011-11-21 | ||
| IQ370/2011 | 2011-11-21 | ||
| US201261624564P | 2012-04-16 | 2012-04-16 | |
| US61/624,564 | 2012-04-16 | ||
| PCT/US2012/041310 WO2013077907A1 (en) | 2011-11-21 | 2012-06-07 | Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504430A JP2015504430A (ja) | 2015-02-12 |
| JP2015504430A5 true JP2015504430A5 (https=) | 2015-07-23 |
Family
ID=48470189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014542299A Pending JP2015504430A (ja) | 2011-11-21 | 2012-06-07 | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150064193A1 (https=) |
| EP (1) | EP2783014A1 (https=) |
| JP (1) | JP2015504430A (https=) |
| KR (1) | KR20140097178A (https=) |
| CN (1) | CN104011223A (https=) |
| AR (1) | AR086907A1 (https=) |
| AU (1) | AU2012341081B2 (https=) |
| BR (1) | BR112014012101A2 (https=) |
| CA (1) | CA2856252A1 (https=) |
| MX (1) | MX2014006158A (https=) |
| RU (1) | RU2014125071A (https=) |
| WO (1) | WO2013077907A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| PH12013500660B1 (en) | 2010-10-08 | 2017-10-27 | Novartis Ag | Methods of treating psoriasis using il-17 antagonists |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| EP3142645A4 (en) | 2014-05-15 | 2017-12-27 | Rani Therapeutics, LLC | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| MX2017003216A (es) | 2014-09-10 | 2017-05-23 | Novartis Ag | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| US20160244520A1 (en) * | 2015-01-24 | 2016-08-25 | Abbvie Inc. | Compositions and methods for treating psoriatic arthritis |
| MY206805A (en) | 2015-10-27 | 2025-01-08 | UCB Biopharma SRL | Methods of treatment using anti-il-17a/f antibodies |
| MA55149A (fr) * | 2018-11-20 | 2021-09-29 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23 |
| MX2021014953A (es) * | 2019-06-04 | 2022-01-24 | Janssen Biotech Inc | Metodo seguro y eficaz para tratar la artritis psoriasica con el anticuerpo especifico anti-il23. |
| US12497449B2 (en) * | 2019-09-20 | 2025-12-16 | Novartis Ag | Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists |
| BR112023018400A2 (pt) * | 2021-03-12 | 2023-12-12 | Janssen Biotech Inc | Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23 |
| MX2023010705A (es) * | 2021-03-12 | 2023-11-22 | Janssen Biotech Inc | Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23. |
| CN114427001A (zh) * | 2022-01-29 | 2022-05-03 | 中日友好医院(中日友好临床医学研究所) | 基于78个snp位点评估阿达木单抗治疗银屑病有效性的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| CN101326195B9 (zh) | 2005-12-13 | 2022-11-11 | 伊莱利利公司 | 抗il-17抗体 |
| JP5068270B2 (ja) | 2006-01-31 | 2012-11-07 | ノバルティス アーゲー | 癌を処置するためのｉｌ−１７アンタゴニスト抗体 |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| CA2690568A1 (en) * | 2007-06-20 | 2008-12-24 | Schering Corporation | Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease |
| JP5581323B2 (ja) | 2008-09-29 | 2014-08-27 | ロシュ グリクアート アクチェンゲゼルシャフト | ヒトｉｌ１７に対する抗体およびその使用 |
| US20120178100A1 (en) * | 2009-07-28 | 2012-07-12 | Centocor Ortho Biotech Inc. | Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis |
| PH12013500660B1 (en) * | 2010-10-08 | 2017-10-27 | Novartis Ag | Methods of treating psoriasis using il-17 antagonists |
| TW201307845A (zh) * | 2010-12-13 | 2013-02-16 | Novartis Ag | 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法 |
-
2012
- 2012-06-07 CA CA2856252A patent/CA2856252A1/en not_active Abandoned
- 2012-06-07 WO PCT/US2012/041310 patent/WO2013077907A1/en not_active Ceased
- 2012-06-07 US US14/358,504 patent/US20150064193A1/en not_active Abandoned
- 2012-06-07 AU AU2012341081A patent/AU2012341081B2/en not_active Ceased
- 2012-06-07 KR KR1020147013196A patent/KR20140097178A/ko not_active Withdrawn
- 2012-06-07 BR BR112014012101A patent/BR112014012101A2/pt not_active IP Right Cessation
- 2012-06-07 CN CN201280057295.5A patent/CN104011223A/zh active Pending
- 2012-06-07 MX MX2014006158A patent/MX2014006158A/es unknown
- 2012-06-07 RU RU2014125071/10A patent/RU2014125071A/ru not_active Application Discontinuation
- 2012-06-07 JP JP2014542299A patent/JP2015504430A/ja active Pending
- 2012-06-07 EP EP12727081.7A patent/EP2783014A1/en not_active Withdrawn
- 2012-06-11 AR ARP120102076A patent/AR086907A1/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504430A5 (https=) | ||
| RU2014125071A (ru) | Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa | |
| RU2014146594A (ru) | Способы лечения анкилозирующего спондилита с использованием антагонистов il-17 | |
| US12269873B2 (en) | Signature of TL1A (TNFSF15) signaling pathway | |
| JP2017513937A5 (https=) | ||
| RU2016144177A (ru) | Способы избирательного лечения астмы с использованием антагонистов il-13 | |
| US20100316608A1 (en) | Method of Determining A Response To Treatment With Immunomodulatory Composition | |
| CA2714410A1 (en) | Disease markers and uses thereof | |
| JP2009039107A5 (https=) | ||
| van Sorge et al. | Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms | |
| JP2017519498A5 (https=) | ||
| WO2016022589A2 (en) | Methods for treating multiple myeloma | |
| EP3390449A1 (en) | Antibodies to risperidone and use thereof | |
| Bojarojc-Nosowicz et al. | Polymorphism and expression of the tumour necrosis factor-alpha (TNF-alpha) gene in non-infected cows and in cows naturally infected with the bovine leukaemia virus (BLV). | |
| CN102808030A (zh) | 单核苷多态性rs3888188在检测结核病易感性中的应用 | |
| WO2011146985A1 (en) | Method of determining response to treatment with immunomodulatory composition | |
| US20210148910A1 (en) | Compositions and methods for treatment of atopic dermatitis and treatment selection | |
| US20100092468A1 (en) | Method for predicting therapeutic responsiveness to tnf-alpha blocking agents | |
| JP2019520355A5 (https=) | ||
| WO2013107005A1 (zh) | 人稀有血型的多重pcr检测方法和试剂盒 | |
| Jiao et al. | Gene analysis of two cases with CisAB/B blood subgroup | |
| US20180258475A1 (en) | Method and device for snp genotyping | |
| Parasannanavar et al. | HLA-DRβ1* 04 typing by simple in-house PCR-SSP technique for rheumatoid arthritis patients | |
| WO2002079503A1 (en) | An allele of apolipoprotein e linked to neuropsychiatric disorders | |
| CN115976183A (zh) | 预测干扰素α对乙型肝炎患者治疗疗效的分子标记及其应用 |